Pfizer and AstraZeneca naming R&D leaders and appointments at APV and Lonza – People on the move
Pfizer has appointed Mikael Dolsten as president of worldwide research and development (R&D). Dolsten joined Wyeth in 2008 and took the post of president, biotherapeutics R&D after the takeover by Pfizer. He has also worked at AstraZeneca (AZ) and Boehringer Ingelheim.
The move marks the end of biologics and small molecule development separation at Pfizer. Martin Mackay led the small molecule wing but has now left to join AZ as president of R&D. Mackay joined Pfizer in 1995 having worked at Cell Biology, CNS Research and Ciba-Geigy.
Lonza has named Lukas Utiger as chief operating officer (COO) of the bioscience division. Utiger is currently COO of Lonza life science ingredients, replacing Anja Fiedler who has resigned for personal health reasons.
Hermann Osterwald has been reappointed treasurer and to the board of the International Association for Pharmaceutical Technology (APV). Osterwald is managing director, contract manufacturing services at NextPharma.
ElexoPharm has appointed Jurgen Engel as chairman of its advisory board. Engel is the current president and CEO of Æterna Zentaris and also serves as a director of the board at Isotechnika.
Natasha Giordano has been promoted to president and CEO of Xanodyne Pharmaceuticals, succeeding Michael Valentino. Giordano most recently worked as COO at Xanodyne and has also held positions at Cegedim Dendrite, Pfizer and Parke-Davis.
aTyr has named John Mendlein as a member of its board of directors. Mendlein is currently chairman of Fate Therapeutics and Alevium Pharmaceuticals. He has also held positions at Adnexus Therapeutics, Aurora Biosciences and Affinium Pharmaceuticals.